The Effectiveness of Subcutaneons Sumatriptan in the Treatment Migrain Attacks
Tahir K. YOLDAŞ1, Abdullah GÜNEN2, Yılmaz SADIKOĞLU2, Refik A. SARI3, Mehmet MEŞHUR4, Emin KURT5
1Nöroloji Anabilim Dalı,Celal Bayar Üniverstesi Tıp, Fakültesi, MANİSA
2KBB Anabilim Dalı, Celal Bayar Üniverstesi Tıp, Fakültesi, MANİSA
3İç Hastalıkları Anabilim Dalı, Celal Bayar Üniverstesi Tıp, Fakültesi, MANİSA
4Fizik Tedavi ve Rehabilitasyon Anabilim Dalı, Celal Bayar Üniverstesi Tıp, Fakültesi, MANİSA.
5Göz Hastalıkları Anabilim Dalı, Celal Bayar Üniverstesi Tıp, Fakültesi, MANİSA
Keywords: Migraine, subcutaneous injection, sumatriptan
Abstract
In this study, the eficacy and safety of sumatriptan, a selective 5-HT1-like receptor agonist,were studied in 97 patients suffering a mild to severe migrain attacks. The patients wereseperated in two groups, 63 patients treated with subcutaneous sumatriptan and 34 patientstreated with placebo. In headache severity, 89 % of patients with sumatriptan achievedmeaningful relief compared with 27 % treated with placebo at 2 hours (P <0.001 ).Miraine-associated symptoms sucb as nausea, photophia, and phonopbohia weresignificantly reduced in the sumntriptan group (P< .001). Sumatriptan was generallywell-tolerated, despite being associated with more adverse events than placebo, because mostadverse events were minor and transient in nature. For this reason, we have consedered thatsubcutaneous sumatriptanis an ejfective and safety treatment for migraine attacks.